Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
My sense on this is that it is a lot of hype this week not by company but by day traders however there are longshot chances. Company seems to be relatively conservative.

With DMD -- There are big boys like Pfizer going after gene therapy complete cure...

CAPR HOPE-2 has demonstrated a treatment that works to delay disease progression in people with advanced disease (non-ambulatory). So this is a conservative approach to go after the sicker patients since this is terminal illness but patents do live into their 20's so FDA wouldn't want to harm them further in their early stages of progression. If it works well with these patients may have more trials to be moved to earlier in the disease cycle.

But if one of the gene therapy complete cures comes through it will basically wipe out or at least reduce substantially the CAP-1002 market and CAP-1002 would be 3rd or 4th line treatment class.

The traders talk about Sarpeta which has 12 Billion market cap and stated potential 2 billion annual revs from its 'inferior' DMD treatment. So that is the hype running on on the stock... CAPR is 200 million market cap.

It seems to have a shot as a long term small percentage speculative position or maybe swing the day trader hype.

Up 30% yesterday, down 10% this AM.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.